Drug Information

Drug General Information
Drug ID
D04HDZ
Former ID
DCL000821
Drug Name
GRN163
Drug Type
Small molecular drug
Indication Multiple myeloma [ICD9: 203; ICD10:C90] Phase 1 [537114]
Company
Geron Corp
Structure
Download
2D MOL

3D MOL
Formula
C15H26B3N3O8P2S2-2
Canonical SMILES
[B]C1CC(C(O1)COP(=O)(NC2CC(OC2COP(=S)(NC3CC(OC3CO)[B])[<br />O-])[B])[S-])N
InChI
1S/C15H28B3N3O8P2S2/c16-13-1-7(19)11(28-13)5-25-31(24,33)21-9-3-15(18)29-12(9)6-26-30(23,32)20-8-2-14(17)27-10(8)4-22/h7-15,22H,1-6,19H2,(H2,20,23,32)(H2,21,24,33)/p-2
InChIKey
HHVGDFKKILAWTA-UHFFFAOYSA-L
PubChem Compound ID
56603713
PubChem Substance ID
53787596, 134339293, 135273968
Target and Pathway
Target(s) Telomerase reverse transcriptase Target Info Inhibitor [537114]
NetPath Pathway IL2 Signaling Pathway
Pathway Interaction Database Validated targets of C-MYC transcriptional activation
Regulation of Telomerase
IL2 signaling events mediated by PI3K
Regulation of nuclear beta catenin signaling and target gene transcription
HIF-1-alpha transcription factor network
Reactome Formation of the beta-catenin:TCF transactivating complex
References
Ref 537114Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
Ref 537114Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.